SUBSCRIBE

Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Kymab in consortium to develop Ebola drug using mouse mAb tech platform

Kymab has received a grant from the UK’s Wellcome Trust to develop treatments against Ebola using its human antibody discovery platform, Kymouse.

EU court opens the door for patents for stem cell treatments

In a reversal from three years ago, the Court of Justice of the European Union (CJEU) ruled on Thursday that an organism incapable of developing into a human being is not a human embryo and may be patented.

Harvard, Korean scientists develop new material to help deliver 3D vaccines

Korean and Harvard University scientists have developed a way to non–surgically inject programmable biomaterial to deliver a 3D vaccine that can more effectively treat diseases like cancer or HIV.

Immunotherapy in the UK? National manufacturing site backed by GE

GE Healthcare has pledged its support and technology to a national £55m ($86m) Cell Therapy manufacturing centre in Stevenage, UK, set to launch in 2017.

Biocon planning new biomanufacturing plant in India

Indian drugmaker and biosimilars pioneer Biocon has told the Chief Minister of Andhra Pradesh it intends to set up a new biomanufacturing plant.

Rouble trouble: Big Pharma exposure to Russian currency volatility limited

Big Pharma firms’ exposure to Russia’s volatile rouble is limited and planned manufacturing investments will go ahead according to observers.

Baxter exits vaccines business as it preps for biopharma spinout

Baxter has sold its pandemic flu portfolio and Vero cell technology to Nanotherapeutics in preparation for the launch of its haematology and oncology-based spinout company Baxalta. 

Singapore develops plan to support influx of biomanufacturing

Industry heavyweights and Singaporean development groups have unveiled a five-year roadmap to deal with the need for more employees in the fast-growing biologics manufacturing industry on the island.

Spotlight

AstraZeneca shutting asthma drug plant as pipeline shifts to biologics

AstraZeneca shutting asthma drug plant as pipeline shifts to biologics

AstraZeneca has continued the Big Pharma trend away from small molecule blockbusters and towards a biologics-heavy pipeline,...

Increased dealmaking will launch stem cell therapies within 5 years

Report: Increased dealmaking will launch stem cell therapies within 5 years

Stem cell therapies are on the brink of breaking through into the mainstream drug market, according to...

Reports of Pierre Fabre's pharma death greatly exaggerated? Cancer mAb R&D to continue

Reports of Pierre Fabre's pharma death greatly exaggerated? Cancer mAb R&D to continue

Pierre Fabre has spared its biopharmaceutical research team from job cuts unveiled last night, signalling that high...

Biopharma's margins can withstand Capex increases after tech sector M&As, expert

Biopharma's margins can withstand Capex increases after tech sector M&As, expert

High margins mean biopharmas can absorb technology price increases after a year of supplier consolidation according to...

Indian company launches world’s first Humira biosimilar

Indian company launches world’s first Humira biosimilar

The first rival to AbbVie’s mega-blockbuster arthritis treatment Humira has hit the shelves in India, with Zydus...

Horizon Discovery enters crowded CHO cell line market

Horizon Discovery enters crowded CHO cell line market

Horizon Discovery Group announced Monday that its bioproduction division has shipped its first commercially available engineered CHO...

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

Biosimilars: developing, manufacturing and selling
William Reed Business Media
All supplier webinars